Replimune Group Inc (NASDAQ:REPL) Sees Large Increase in Short Interest

Replimune Group Inc (NASDAQ:REPL) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 635,300 shares, an increase of 14.2% from the September 30th total of 556,300 shares. Based on an average daily volume of 59,000 shares, the short-interest ratio is currently 10.8 days. Approximately 8.0% of the company’s stock are sold short.

Several equities research analysts recently commented on the stock. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Replimune Group in a research note on Thursday, October 24th. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Replimune Group in a research note on Monday, September 30th. Zacks Investment Research lowered shares of Replimune Group from a “buy” rating to a “hold” rating in a research note on Friday. Roth Capital lifted their price target on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, ValuEngine upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Replimune Group currently has an average rating of “Buy” and an average target price of $25.17.

In related news, COO Colin Love sold 11,250 shares of Replimune Group stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $17.05, for a total transaction of $191,812.50. Also, CEO Robert Coffin sold 48,500 shares of Replimune Group stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $16.92, for a total transaction of $820,620.00. Over the last ninety days, insiders have sold 200,000 shares of company stock valued at $3,395,500. Corporate insiders own 63.18% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in REPL. Morgan Stanley lifted its holdings in shares of Replimune Group by 793.0% in the second quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after purchasing an additional 18,390 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Replimune Group by 211.3% in the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after purchasing an additional 15,672 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Replimune Group by 1.2% in the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,437 shares in the last quarter. Citadel Advisors LLC lifted its holdings in shares of Replimune Group by 5.7% in the second quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock valued at $2,731,000 after purchasing an additional 10,009 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Replimune Group by 7.3% in the second quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock valued at $7,866,000 after purchasing an additional 36,547 shares in the last quarter. 60.92% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ REPL traded down $1.44 during trading on Friday, reaching $12.20. The company’s stock had a trading volume of 819,800 shares, compared to its average volume of 194,376. The firm has a market cap of $436.60 million, a price-to-earnings ratio of -9.17 and a beta of 3.30. Replimune Group has a twelve month low of $8.88 and a twelve month high of $18.25. The business’s fifty day moving average price is $14.49 and its 200-day moving average price is $13.44. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.79 and a current ratio of 9.85.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, sell-side analysts forecast that Replimune Group will post -1.4 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: What are the FAANG Stocks?

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.